Will Van Derveer
Will Van Derveer, MD, is a physician working in the field of mental health. His published research includes an investigation into skill retention among Wilderness First Responders, published in the journal Wilderness & Environmental Medicine.
24 claims checked on air: 3 context 3 contradicted 1 overstated 14 supported 3 unverified 4 flagged
What they said on air - context
Walking 10,000 steps per day reduces Alzheimer's disease risk by 50%.
"I remember a recent post you put up which I loved of you want to reduce your Alzheimer's risk by 50%, get 10,000 steps." (said at 0:28:35)
A prospective cohort study of 78,430 UK Biobank adults using wrist-worn accelerometers (del Pozo Cruz et al., JAMA Neurology, 2022) found that an optimal daily step count of 9,826 steps was associated with a 51% lower risk of incident dementia (hazard ratio 0.49; 95% CI, 0.39-0.62) over a median follow-up of 6.9 years. While the numerical claim closely mirrors these published findings (~10,000 steps and ~50% risk reduction), the study evaluated all-cause dementia rather than Alzheimer's disease specifically, and the observational cohort design demonstrates an association rather than definitive causal prevention.
Brain imaging of the default mode network shows schizophrenia and significant dissociative disorders have a loose electrical patterning compared to obsessive ruminative states.
"Well, a diagnosis of schizophrenia um particularly uh would be something that or or someone who has a um significant dissociative disorder. Uh these are both situations that we know from looking at the default mode network, the electrical patterning in the brain um have what we would call maybe a loose pattern or uh the opposite of the person who is considered to be a really good candidate for psychedelic therapy" (said at 0:34:07)
The speaker's description colloquially reflects theoretical frameworks in neuropsychopharmacology (such as the Entropic Brain and REBUS models developed by Carhart-Harris and colleagues), which propose that high-entropy, disorganized, or "loose" brain network dynamics occur in states like early psychosis and under psychedelic administration, contrasting with the low-entropy, overly rigid or hyper-constrained default mode network (DMN) activity seen in obsessive-compulsive disorders and depressive rumination. However, referring to schizophrenia and dissociative disorders as having a simple "loose electrical pattern" in the DMN is an oversimplification. Neuroimaging and electrophysiological studies in schizophrenia and dissociative states report complex, heterogeneous, and frequency-dependent alterations—including both regional hyperconnectivity and hypoconnectivity across DMN subregions and related networks—rather than a uniform "loose" pattern.
An ayahuasca experience typically lasts between 6 and 8 hours, whereas an ibogaine experience lasts around 72 hours.
"the ayahuasca experience tends to be about 6 hours, maybe 8 hours. Uh if you do booster doses, it could be longer. The Ibogaine experience is way longer. It it's usually more like 72 hours where you are completely uh dependent on your caregivers." (said at 1:01:14)
The speaker's comparison accurately reflects the substantial difference in duration between ayahuasca and ibogaine, though the exact figures require nuance regarding acute pharmacological action versus full multi-phase recovery. In controlled clinical trials, a single dose of ayahuasca produces subjective effects beginning within 30 to 60 minutes, peaking at 60 to 120 minutes, and largely resolving by 240 minutes (4 hours), though ceremonial settings involving redosing typically span 6 to 8 hours. In contrast, the subjective and physiological effects of flood-dose ibogaine are markedly prolonged: the acute visionary/oneiric phase typically lasts 24 to 36 hours, while the subsequent cognitive, motor (ataxia), and reflective recovery phases routinely require medical supervision and caregiver dependence for 48 to 72 hours.
Fact-checked episodes
Publications